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Abstract
Background: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and death. Drug use remains the
significant cause of new infections in the European Union, with estimates of HCV antibody prevalence among people who inject
drugs ranging from 5% to 90% in 29 European countries. In Ireland and the European Union, primary care is a key area to focus
efforts to enhance HCV diagnosis and treatment among people who inject drugs.
Objective: The Heplink study aims to improve HCV care outcomes among opiate substitution therapy (OST) patients in general
practice by developing an integrated model of HCV care and evaluating its feasibility, acceptability, and likely efficacy.
Methods: The integrated model of care comprises education of community practitioners, outreach of an HCV-trained nurse
into general practitioner (GP) practices, and enhanced access of patients to community-based evaluation of their HCV disease
(including a novel approach to diagnosis, that is, Echosens FibroScan Mini 430). A total of 24 OST-prescribing GP practices
were recruited from the professional networks and databases of members of the research consortium. Patients were eligible if
they are aged ≥18 years, on OST, and attend the practice for any reason during the recruitment period. Baseline data on HCV
care processes and outcomes were extracted from the clinical records of participating patients.
Results: This study is ongoing and has the potential to make an important impact on patient care and provide high-quality
evidence to help GPs make important decisions on HCV testing and onward referral.
Conclusions: A substantial proportion of HCV-positive patients on OST in general practice are not engaged with specialist
hospital services but qualify for direct-acting antiviral drugs treatment. The Heplink model has the potential to reduce HCV-related
morbidity and mortality.
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Introduction
Hepatitis C as a Global Challenge
With approximately 71 million people affected worldwide and
399,000 related deaths, chronic hepatitis C virus (HCV) infection
is associated with considerable morbidity, including cirrhosis
and hepatocellular carcinoma [1]. Injecting drug use remains
the significant cause of new infections in the European Union,
with estimates of HCV antibody prevalence among people who
inject drugs (PWID) ranging from 5% to 90% in 29 European
countries [2]. With successful treatment and viral eradication,
recent data have demonstrated decreases in all-cause mortality,
mortality due to cirrhosis, and the incidence of hepatocellular
carcinoma [3-5].
Recently developed HCV direct-acting antiviral drugs are well
tolerated and delivered for shorter courses (8-12 weeks), with
trials reporting more than 90% cure rates among PWID [6].
Despite these highly effective and simplified therapeutic
regimens, many people at risk are unaware of their infection,
and obstacles limit access to HCV care, resulting in many
patients not being treated [7].
Notwithstanding these challenges, the World Health
Organization has set a goal of eliminating viral hepatitis as a
major public health threat by 2030, reducing new chronic
infections by 90% and reducing mortality by 65% [8]. In most
countries, the scale-up of HCV treatment for PWID, along with
needle and syringe programs and opiate substitution therapy
(OST), will be key to these targets being achieved.
Enhancing Access to Treatment
Reaching and engaging PWID with HCV are key challenges,
given the prohibition surrounding illicit and injecting drug use
and the resultant stigma and discrimination concerns and
possible mistrust of health services [9]. Community and peer
involvement is likely to be critical to the success of HCV
prevention programs for PWID. It has also been hypothesized
by some clinicians and researchers that successful treatment of
HCV in PWID can improve recovery and engagement with
addiction treatment [10].
Blood tests and liver biopsy were historically the standard
approach to assess the need for treatment in those with chronic
HCV infection. However, many patients have defaulted from
HCV care because of perceived dangers associated with liver
biopsy [11]. More recently, alternative diagnostic modalities
including liver stiffness measurement by transient elastography
(Echosens FibroScan Mini 430) have resulted in noninvasive
approaches to stage fibrosis. Several European studies have
recently reported on the feasibility of fibroscanning as a
screening tool for drug users, with high rates of acceptance and
uptake within various treatment and street outreach settings
[12,13].The mobility of this equipment means it can be
transported to community sites to access patients, and for PWID,
this procedure can help assess disease severity, enhance HCV
assessment, reduce patient identified barriers, target therapy,
and enable the triage of patients for more immediate care
[14-16].
The Role of Primary and Community-Based Care
In Ireland and the European Union, primary care is increasingly
providing long-term care for PWID. Although screening and
identification practices are inconsistent, 62% to 81% of this
population are infected with HCV [17,18]. Furthermore, research
indicates 35% of patients attending general practitioners (GPs)
for OST in Ireland also had problem alcohol use (PAU) [19],
and a subsequent qualitative study highlighted the need for
primary care to address this problem through screening and
brief intervention [20]. The study recommended initial screening
for PAU by the patient’s GP using the Alcohol Use Disorders
Identification Test (AUDIT) screening tool [21] and providing
feedback on results in all cases with positive findings through
a brief intervention involving advice on minimizing alcohol
harm, encouraging a reduction in alcohol consumption, and
initiating referral to specialists when needed. Thus, primary care
is a key area to focus efforts to enhance HCV diagnosis and
treatment among PWID. However, a number of challenges exist
in this regard, including for PWID: lack of awareness, fear of
side effects for HCV drugs, possible poor adherence, and
comorbid conditions; and for health care providers, limited
knowledge and communication difficulties may be problematic
[16,22,23]. These challenges can be addressed through
education, audit and feedback, and liaison nurse support [24,25].
Research has demonstrated that if adequately supported, primary
care and specifically general practice could adequately screen
for HCV [26]. Research indicates that offering primary care
practice staff training on the epidemiology, diagnosis, and
management of HCV infection, so increasing testing of HCV
was cost-effective [27]. Furthermore, testing PWID in primary
care may also identify patients who have been diagnosed
previously but have not been referred to, or failed to attend
specialist care, offering the opportunity to review and follow-up
such referrals.
Aims
This Heplink study forms part of a European Union–funded
program of research (HepCare Europe) which aims to optimize
hepatitis C diagnosis; linkage between primary, secondary, and
outreach community care; and access to treatment for at
risk-populations in the European Union.
The Heplink study focuses specifically on developing complex
interventions to enhance community-based HCV treatment and
improve the HCV care pathway between primary care and
secondary care. As such, Heplink is a prospective,
nonrandomized pre-post intervention feasibility study in primary
care to identify and invite patients on OST to undergo testing,
with referral to secondary care, where appropriate. We will
evaluate the feasibility, acceptability, and likely efficacy of this
approach quantitatively, qualitatively, and through assessing its
cost-effectiveness. The specific objectives of the study are to
develop and implement an integrated model of HCV care and
evaluate its feasibility, acceptability, likely efficacy, and
cost-effectiveness in practice.
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Methods
Study Design and Setting
This is a prospective, nonrandomized, pre-post intervention
feasibility study to be conducted in OST-prescribing general
practices from three sites across the Hepcare Europe consortium
(Dublin, London, and Seville). Practices will be given written
information on the study and asked to indicate their interest in
participating. Our recent experience recruiting general practices
[28,29] has taught us the importance of a researcher promptly
following up an expression of interest from a GP to fully explain
the study and highlight what will be required from the GP in
terms of time and commitment to the study. As such, practices
who express an interest in participating will be contacted by a
member of the research team to explain the aims of the study
and what is required.
Study Population
A sample of 24 OST-prescribing GP practices will be recruited
from the professional networks of members of the research
consortium.
Practices will be eligible to participate if they are registered to
prescribe methadone and have at least 10 patients currently
receiving OST; agree to participate in practice audit; and (3)
agree to facilitate nurse liaison.
Patients (n=240) will be eligible to participate if they are on
OST (ie, methadone); are aged at least 18 years; and attend the
practice for any reason during the recruitment period.
Approach to Sampling and Recruitment
A standardized nonprobability sampling framework will be used
to identify 10 consecutive patients from each practice or center
to participate in the study. On the basis of the recommendations
for good practice in feasibility studies [30] and our previous
work conducting feasibility studies with PWID [29,31], we
estimate that 240 patients (attending 24 general practices) will
be adequate to calculate the actual recruitment and retention
rates (ie, feasibility) and provide data on acceptability of study
processes and outcome measures, which will inform a future
definitive trial. This approach to recruitment reflects the
challenges involved in recruiting this population group for
projects. Patients who consult a doctor or nurse in participating
practices or centers and who are eligible for the study will be
given written information and a verbal explanation of the study,
including the study purpose, procedures, and how findings will
be utilized. Those who are interested in participating will be
asked to sign a consent form, which will be witnessed by the
doctor or nurse or the researcher. Although the initial approach
to participate will be from a health care professional, recruitment
will be facilitated by a member of the research team being “on
site” to support the practice during the recruitment phase and
answer any questions potential participants may have. The
recruitment phase will involve each participating practice
engaging in an intensive, 4-week period of patient recruitment,
an approach we found most effective in previous work with this
population [28,29]. During this 4-week period, the member of
the research team will aim to (1) obtain contact details for and
informed consent from eligible patients, (2) review the clinical
records of patients who consent to participate in the study, and
(3) collect baseline data, including patient demographics and
current care process and outcome measures from clinical
records.
Intervention
Informed by the UK Medical Research Council “Framework
for design and evaluation of complex interventions to improve
health” [32], the aim of the intervention is to enhance
identification and linkage to HCV care and treatment among
patients attending primary care for OST and includes the
following (see Figure 1):
• Outreach of an HCV-trained liaison nurse into GP practices
• In-practice education for GPs and practice staff regarding
developments in diagnosis and treatment of HCV
• Enhanced access of patients to community-based evaluation
of HCV disease, including a novel approach to diagnosis,
that is, transient elastography (Echosens FibroScan Mini
430)
• Researcher-facilitated practice audit of HCV care processes
and feedback to GP
Data Collection
Data on patient demographics and HCV care processes/outcomes
will be extracted from the patient’s clinical electronic or paper
medical record and also from patient self-reported data collected
through the HCV liaison nurse assessment to include the
following:
• Prior HCV testing
• HCV status—antibody and Ribonucleic Acid (RNA) or
antigen
• Referral and attendance for HCV care at a hospital’s
Department of Hepatology or Infectious Diseases
• HCV assessment and treatment and sustained virological
response (SVR)
• Alcohol screening and brief intervention using a validated
alcohol screening instrument (eg, AUDIT)
• Other blood borne virus (BBV): HIV and hepatitis B virus
(HBV)
• BBV testing/vaccination: liaison nurse will assess if the
patient has been tested for HCV, HIV, and whether HBV
immunization is required
• Chronic illness
• Mortality
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Figure 1. Flowchart of the nurse-led intervention. GP: general practitioner; HCV Ab: HCV antibody; HCV: hepatitis C virus; ID: infectious diseases;
MMUH: Mater Misericordiae University Hospital; PCR: polymerase chain reaction; OPD: Outpatient Department; OST: opiate substitution therapy;
RNA: Ribonucleic Acid; Ag/RNA: Antigen/Ribonucleic Acid.
The HCV liaison nurse will meet and assess the patient,
addressing any questions they may have regarding their HCV
status. The liaison nurse will also gather data on the following
variables:
• HCV risk factors (eg, incarcerated, tattoos, piercings, blood
transfusion, sexually transmitted infection test)
• OST treatment
• Alcohol use assessed using the AUDIT questionnaire
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• HCV testing, assessment, and treatment history
• Other BBV testing and HBV and hepatitis A virus
vaccination history
• Quality of life (EQ5D-3L)—collected by HCV liaison nurse
just before their assessment and intervention where
necessary with each patient
• HCV-antibody positive and Ribonucleic Acid/Antigen
(RNA/Ag) status (positive or unknown)
• Echosens FibroScan Mini 430 data (the nurse will have
received Echosens FibroScan Mini 430 training)
After the assessment, the liaison nurse will provide the patient
with information/education regarding HCV, including how it
is transmitted and how to prevent transmission. Harm reduction
strategies will also be addressed if required. A handover of the
nurse’s assessment will be given to the GP. HCV Ab+ patients
will be referred to specialist services if they are Ag+, RNA+,
or if Ag and RNA status are unknown. This process will be
carried out by the GP with the assistance of the HCV liaison
nurse. Referrals are submitted to the hospital’s Hepatology or
Infectious Diseases department.
Qualitative Data Collection
Semistructured interviews will be conducted by a member of
the research team with health care professionals (n=12) and
patients (n=12; or until analytical saturation is reached) at
follow-up, purposively sampled from recruited practices and
patients. Interviews will be guided by an interview schedule
informed by our previous feasibility study in Irish primary care
[33], including participants’ lived experiences of HCV including
barriers and facilitators to treatment, as well as questions
exploring participants’ experiences and acceptability of the
study intervention. With purposive sampling, the researcher
samples particular settings, persons, or events deliberately
selected for the important information they can provide that
cannot be acquired as well from other choices [34]. In line with
the simultaneous analysis and collection of data that is an
integral part of qualitative analysis, after the first 3 health care
professional and first 3 patient interviews, recruitment will be
informed by themes identified in the data. Participants recruited
for the qualitative data collection will be provided with an
amended participant information leaflet outlining the purpose
of this part of the study, and, if agreeable, asked to sign a
separate consent form.
Outcome Measures
To establish the feasibility, acceptability, and likely efficacy of
this intervention in practice, the following outcome measures
will be examined (see Table 1 for measures to establish
feasibility, acceptability, and likely efficacy):
Primary outcomes include the following:
• Proportion of participants who have been screened for HCV
• Proportion of HCV antibody–positive patients commenced
on/completed antiviral therapy/achieved SVR
Secondary outcomes include the following:
• Proportion of those screened who tested HCV antibody
positive
• Proportion of HCV-positive patients who have been
assessed by Echosens FibroScan Mini 430
• Proportion of HCV-positive patients who have been referred
to specialist hepatology or infectious diseases service
• Proportion of HCV-positive patients who have attended
specialist hepatology or infectious diseases service
• Proportion of HCV-positive patients received an alcohol
screening brief intervention
• Proportion of participants tested for anti-HIV antibody,
anti-HBc (hepatitis B core) antibody, or hepatitis B surface
antigen (HBsAg)
• Proportion of participants immunized against hepatitis B/A
virus
• Experience and evaluation of the intervention among key
informants (GPs, nurses, and patients)
• Number of patients attending general practice for OST
postintervention for follow-up testing
• Evaluate feasibility and possible efficacy of intervention
by comparing pre-post intervention data
• Evaluate the cost-effectiveness of the intervention
• Compare GPs’ and practice nurses’ knowledge and attitudes
and practice pre-post intervention
Data Analysis
Quantitative data will be analyzed using SPSS v22.
Questionnaires will be summarized using descriptive statistics,
and a pre-post intervention analysis will be performed using
Fisher exact test.
Semistructured interview transcripts will be checked for
accuracy and then imported into NVivo10 qualitative data
analysis software to aid management and analysis of data.
Analysis will begin shortly after data collection starts and will
be ongoing and iterative. Analysis will inform further data
collection; for instance, analytic insights from data gathered in
earlier interviews will help identify any changes that need to be
made to the topic guide during later interviews. Thematic
analysis [35] using a data-driven inductive approach will be
used to scrutinize the data to identify and analyze patterns and
themes of particular salience for participants and across the
dataset. The first author (a social psychologist with extensive
experience in using qualitative methodologies) will analyze and
code the data. The data will also be independently analyzed by
the second author who also has extensive expertise in qualitative
research. Final themes will be agreed between the 2 authors,
and the last author will audit the final analysis.
The goals of this study are to examine feasibility, acceptability,
and likely efficacy of the intervention. Descriptive statistics will
be analyzed with respect to key feasibility variables. The
qualitative analysis of patients’ and health care professionals’
experiences of the intervention will be used to assess
acceptability. Although the study is not designed to determine
effectiveness, we will examine likely efficacy by comparing
process and outcome measures, which will allow estimation of
the intracluster correlation coefficient and thus inform the
sample size of a possible future definitive trial.
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Table 1. Measures to establish feasibility, acceptability, and likely efficacy.
Practice levelPatient levelAim
Compare pre-post intervention data on patient demographics,
HCV care processes and outcomes extracted from patients’
clinical electronic or paper medical records, and also from pa-
tient self-reported data collected through the HCV liaison nurse
assessment; practice recruitment rates; practice retention level;
cost-effectiveness of the intervention
Compare pre-post intervention data on patient demographics,
hepatitis C virus (HCV) care processes and outcomes extracted
from patients’ clinical electronic or paper medical records, and also
from patient self-reported data collected through the HCV liaison
nurse assessment; patient recruitment rates; patient retention level;
and cost-effectiveness of the intervention
Feasibility
GPs’a and practice nurses’ experience of intervention evaluated
by analysis of semistructured interviews with patients
Patients’ experience of intervention evaluated by analysis of
semistructured interviews with patients
Acceptability
Although not adequately powered to examine efficacy, possible
efficacy will be assessed by knowledge and attitudes and prac-
tice pre-post intervention and cost-effectiveness of study
Although not adequately powered to examine efficacy, possible
efficacy will be assessed by proportion of patients who have been
screened for HCV and alcohol use, proportion of patients who have
been referred for treatment (HCV, alcohol), and cost-effectiveness
of study
Likely efficacy
aGP: general practitioner.
Cost-Effectiveness
A cost-effectiveness analysis will be undertaken of the Heplink
intervention. This analysis will be important to investigate
whether this HCV case-finding intervention is a worthwhile
investment.
Costs for the intervention will be collected (in Euros) from the
provider’s perspective using an ingredients-based approach,
including a time and motion study of the nurse liaison activities.
Health-related quality of life information will be collected using
the EQ5D-3L (to calculate QALYs) at the start of the
intervention, as there is a paucity of information for this patient
group, with further quality of life data coming from other
ongoing studies by the team. Using collected cost data and
outcome data from the intervention, the long-term health benefits
and costs of the intervention compared with the current standard
of care will be calculated using a transmission dynamic model
of HCV infection and disease progression. Further data to
parameterize the model (PWID epidemiological and behavioral
data and HCV transmission and progression data) will come
from the published and gray literature. The incremental
cost-effectiveness ratio will be calculated in terms of incremental
cost per QALY saved and compared with the willingness-to-pay
threshold for each country (€45,000 per QALY for Ireland) to
determine whether the intervention is cost-effective.
Ethical Considerations
The study has been approved by the Mater Misericordiae
University Hospital Research Ethics Committee (Ref:
1/378/1722) and the Research Ethics Committees of the
collaborating institutions in London and Seville.
Ethical considerations and safeguards include the following:
• Informed consent and consenting capacity: all potential
participants (GPs, patients) will be given written information
on the study, the model of care being proposed, and asked
to provide written consent that they are happy to participate
and that nonparticipation will not compromise their usual
care. Participation in the study will be on a voluntary basis.
No inducements to participate will be offered.
• Confidentiality: Any data/personal details that could
potentially reveal the identity of individuals will be
removed. Only anonymized, deidentified information will
leave the practice of origin. To allow follow-up, an
alphanumeric code will be assigned to each participant’s
data; a database will be maintained on a password-protected
database at Mater Misericordiae University Hospital. The
list will be kept separately from patient data but will indicate
the medical record number of each participant and the
alphanumeric code. All research data will be stored on a
password-protected desktop computer at the host
organization. Study participants will be invited to give
permission to have their name, address, and contact details
held by the research team to facilitate their receiving a
synopsis of the study findings on publication and to be
contacted for follow-up data collection. All data will be
stored securely at the host institution.
• Clinical governance, do no harm: it is possible that
participating in the study may raise health-related issues
for participants and may identify a health issue that requires
a clinical intervention. Therefore, all participants will be
advised to speak with their doctor if participating in the
study has raised any such issues. At the conclusion of the
intervention, the HCV-trained liaison nurse will conduct a
handover of clinical information to the GP, which includes
recommendations for follow-up care.
Results
The 3-year project is funded, from June 2016, by the European
Union Third Health Programme (grant agreement number
709844) and Ireland’s Health Services Executive. Data
collection will be completed by July 2018, and data analysis is
currently ongoing, with the findings expected to be submitted
for publication in late 2018. Baseline data results from the
Dublin arm of the study were submitted for publication in March
2018. The study findings have the potential to make an important
impact on patient care and provide high-quality evidence to
help GPs make important decisions on HCV testing and onward
referral.
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Discussion
Strengths and Limitations
“Heplink” is the first study to examine the feasibility and
acceptability of integrated HCV care among problem drug users
attending primary care in Europe. It will provide key data to
enhance scientific understanding of interventions that prevent
risk behaviors, inform policy and service development, and
contribute to health and social gain locally and internationally.
This study has the potential to make an important impact on
patient care and will provide high-quality evidence to help GPs
make important decisions on HCV testing and onward referral.
The intervention is scalable and, therefore, if found to be
feasible, acceptable, and cost-effective, it can be readily
implemented elsewhere and used to guide policy and service
development internationally.
Possible limitations of the study include potential issues of bias
and lack of generalizability that may arise from the recruitment
process, resulting in the likelihood that GPs who are more
motivated and interested in research and innovation will choose
to participate. Although target patient sample of 240 patients is
relatively small for a trial study, it will allow us to estimate the
sample size required for a future definitive trial.
The project team involves academic, clinical, and policy experts
responsible for planning and delivery of addiction care and
primary care and international experts on optimum primary care
delivery to at-risk populations and primary care alcohol
treatment.
The proposed work builds on our previously conducted work
that outlined the barriers and enablers to HCV screening and
treatment in practice and examined the effectiveness of a
nurse-led intervention to enhance HCV screening in primary
care [36].
Conclusions
At the end of this research, the feasibility of a clinical
intervention, informed by international best practice and local
barriers, will be evaluated among a high-risk population. This
feasibility study will inform clinical practice by providing initial
indications as to whether a nurse-led integrated model of HCV
care is feasible, acceptable, and also effective among problem
drug users attending primary care. It will also inform future
research on the topic by providing key parameters for the design
of a future cluster randomized controlled trial.
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